Auxilium Pharmaceuticals (Nasdaq: AUXL) reported earnings on April 29. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Auxilium Pharmaceuticals whiffed on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped. Non-GAAP loss per share expanded. GAAP loss per share grew.

Margins shrank across the board.

Revenue details
 Auxilium Pharmaceuticals reported revenue of $66.2 million. The 10 analysts polled by S&P Capital IQ looked for net sales of $82.1 million on the same basis. GAAP reported sales were 10% lower than the prior-year quarter's $73.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.12. The six earnings estimates compiled by S&P Capital IQ anticipated $0.03 per share. Non-GAAP EPS were -$0.12 for Q1 compared to -$0.04 per share for the prior-year quarter. GAAP EPS were -$0.17 for Q1 versus -$0.04 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 77.2%, 20 basis points worse than the prior-year quarter. Operating margin was -7.7%, 510 basis points worse than the prior-year quarter. Net margin was -12.4%, 1,000 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $92.2 million. On the bottom line, the average EPS estimate is $0.10.

Next year's average estimate for revenue is $377.3 million. The average EPS estimate is $0.31.

Investor sentiment
 The stock has a two-star rating (out of five) at Motley Fool CAPS, with 135 members out of 189 rating the stock outperform, and 54 members rating it underperform. Among 53 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 30 give Auxilium Pharmaceuticals a green thumbs-up, and 23 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Auxilium Pharmaceuticals is outperform, with an average price target of $21.80.